日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to first-line endocrine therapy

病例报告:激素受体阳性、HER2阴性乳腺癌晚期脉络膜转移,一线内分泌治疗有效

Alsharif, Hisham; Wesolowski, Robert; Cebulla, Colleen M; Davenport, Ashley P; Gatti-Mays, Margaret E; Johnson, Kai C C; Lopetegui-Lia, Nerea; Quiroga, Dionisia; Roy, Arya Mariam; Shujaat, Mohammad; Stover, Daniel G; Bader, Gilbert

BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy

BRD4抑制可导致MDSC凋亡并增强免疫检查点阻断疗法的效果。

Savardekar, Himanshu; Stiff, Andrew; Liu, Alvin; Wesolowski, Robert; Schwarz, Emily; Garbarine, Ian C; Duggan, Megan C; Zelinskas, Sara; Li, Jianying; Lapurga, Gabriella; Abreo, Alexander; Savardekar, Lohith; Parker, Ryan; Sabella, Julia; DiVincenzo, Mallory J; Benner, Brooke; Sun, Steven H; Quiroga, Dionisia; Scarberry, Luke; Xin, Gang; Dey, Anup; Ozato, Keiko; Yu, Lianbo; Hasanov, Merve; Sundi, Debasish; Wu, Richard C; Kendra, Kari L; Carson, William E 3rd

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

格达托利西布联合帕博西尼和来曲唑治疗既往未接受过全身治疗的激素受体阳性、HER2阴性晚期乳腺癌患者

Wesolowski, Robert; Rugo, Hope S; Specht, Jennifer M; Han, Hyo S; Kabos, Peter; Vaishampayan, Ulka; Wander, Seth A; Gogineni, Keerthi; Spira, Alexander; Schott, Anne F; Abu-Khalaf, Maysa; Mutka, Sarah C; Suzuki, Samuel; Sullivan, Brian; Gorbatchevsky, Igor; Layman, Rachel M

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results

帕拉塞群(Palazestrant)是一种新型口服完全雌激素受体拮抗剂(CERAN)和选择性雌激素受体降解剂(SERD),用于治疗ER+/HER2-晚期或转移性乳腺癌患者:1/2期研究结果

Hamilton, Erika P; Patel, Manish R; Borges, Virginia F; Meisel, Jane L; Okera, Meena; Alemany, Carlos A; Pluard, Timothy J; Wesolowski, Robert; Sabanathan, Dhanusha; Miller, Kathy D; Conlin, Alison K; McCarthy, Nicole; Shaw, Morena; Tonda, Margaret; Shilkrut, Mark; Lin, Nancy U

Effect of Intolerance of Uncertainty on Perceived Cognitive Function Among Breast Cancer Patients Before Chemotherapy

化疗前乳腺癌患者不确定性容忍度对感知认知功能的影响

Yang, Yesol; Tan, Alai; Sardesai, Sagar D; Williams, Nicole O; Gatti-Mays, Margaret; Stover, Daniel G; Sudheendra, Preeti K; Wesolowski, Robert; Gorka, Stephanie M; Pyter, Leah M

Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis

低激素受体表达对非转移性HER2阴性乳腺癌新辅助化疗反应和治疗模式的影响:一项基于美国国家癌症数据库的分析

Quiroga, Dionisia; Pei, Charles; Stephens, Julie A; Johnson, Kai C C; Williams, Nicole; Sudheendra, Preeti; Cherian, Mathew; Stover, Daniel; Davenport, Ashley; Gatti-Mays, Margaret; Wesolowski, Robert; Bazan, Jose G; Beyer, Sasha; Park, Ko Un; Oppong, Bridget A; White, Julia; Jhawar, Sachin R; Sardesai, Sagar

CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications

CNPY2在实体瘤中的作用机制、生物标志物潜力及治疗意义

Mullick Chowdhury, Sayan; Hong, Feng; Rolfo, Christian; Li, Zihai; He, Kai; Wesolowski, Robert; Mortazavi, Amir; Meng, Lingbin

Size matters: a review of the challenges in and importance of multimodal approaches to the management of patients with small, node-negative, triple-negative breast cancer

肿瘤大小至关重要:对小型、淋巴结阴性、三阴性乳腺癌患者多模式治疗方法所面临的挑战和重要性的回顾

Prasath, Vishnu; To, Briana; Quiroga, Dionisia M; Oppong, Bridget A; Johnson, Kai; Facer, Benjin; Wesolowski, Robert

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

一项针对转移性三阴性乳腺癌患者的MEK抑制剂曲美替尼单药治疗及联合AKT抑制剂GSK2141795/uprosertib治疗的II期研究

Prasath, Vishnu; Boutrid, Hinda; Wesolowski, Robert; Abdel-Rasoul, Mahmoud; Timmers, Cynthia; Lustberg, Maryam; Layman, Rachel M; Macrae, Erin; Mrozek, Ewa; Shapiro, Charles; Glover, Kristyn; Vater, Mark; Budd, G Thomas; Harris, Lyndsay; Isaacs, Claudine; Dees, Claire; Perou, Charles M; Johnson, Gary L; Poklepovic, Andrew; Chen, Helen; Villalona-Calero, Miguel; Carson, William; Stover, Daniel G; Ramaswamy, Bhuvaneswari